{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:42:42Z","timestamp":1780386162163,"version":"3.54.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["CONACYT: I010\/0532\/2014"],"award-info":[{"award-number":["CONACYT: I010\/0532\/2014"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007774","name":"Instituto de Ciencia y Tecnolog\u00eda del Distrito Federal","doi-asserted-by":"publisher","award":["ICyTDF\/279\/2011"],"award-info":[{"award-number":["ICyTDF\/279\/2011"]}],"id":[{"id":"10.13039\/100007774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Comisi\u00f3n de Operaci\u00f3n y Fomento de Actividades Acad\u00e9micas\/Secretar\u00eda de Investigaci\u00f3n y Posgrado-IPN","award":["COFAA-SIP\/IPN: 20160204"],"award-info":[{"award-number":["COFAA-SIP\/IPN: 20160204"]}]},{"DOI":"10.13039\/501100008441","name":"Programa Iberoamericano de Ciencia y Tecnolog\u00eda para el Desarrollo","doi-asserted-by":"crossref","award":["CYTED: 214RT0482"],"award-info":[{"award-number":["CYTED: 214RT0482"]}],"id":[{"id":"10.13039\/501100008441","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["CONACYT: 132353"],"award-info":[{"award-number":["CONACYT: 132353"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Comisi\u00f3n de Operaci\u00f3n y Fomento de Actividades Acad\u00e9micas\/Secretar\u00eda de Investigaci\u00f3n y Posgrado-IPN","award":["COFAA-SIP\/IPN: 20161374"],"award-info":[{"award-number":["COFAA-SIP\/IPN: 20161374"]}]},{"name":"Comisi\u00f3n de Operaci\u00f3n y Fomento de Actividades Acad\u00e9micas\/Secretar\u00eda de Investigaci\u00f3n y Posgrado-IPN","award":["COFAA-SIP\/IPN: 20161383"],"award-info":[{"award-number":["COFAA-SIP\/IPN: 20161383"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0159889","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T17:43:17Z","timestamp":1469468597000},"page":"e0159889","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity"],"prefix":"10.1371","volume":"11","author":[{"given":"Aurelio","family":"Romero-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Guti\u00e9rrez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Correa-Basurto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Cecilia","family":"Rosales Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzia Irene","family":"Padilla Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Elena","family":"Mendieta-Wejebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1001\/jama.2013.4466","article-title":"Management of active Crohn disease","volume":"309","author":"AS Cheifetz","year":"2013","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrgastro.2014.202","article-title":"Epidemiology, risk factors and management of cardiovascular diseases in IBD","volume":"12","author":"S Singh","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1561","article-title":"Vedolizumab for the treatment of moderately to severely active ulcerative colitis","volume":"35","author":"PS Dulai","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11894-015-0453-1","article-title":"Optimizing biologic agents in ulcerative colitis and Crohn&apos;s Disease","volume":"17","author":"A O'Toole","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"13219","DOI":"10.3748\/wjg.v20.i37.13219","article-title":"Crohn&apos;s disease and growth deficiency in children and adolescents","volume":"20","author":"M Gasparetto","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3904\/kjim.2014.29.5.558","article-title":"Crohn&apos;s disease in Korea: past, present, and future","volume":"29","author":"KM Lee","year":"2014","journal-title":"Korean J Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1590\/1414-431X20143774","article-title":"Classical and recent advances in the treatment of inflammatory bowel diseases","volume":"48","author":"H Sales-Campos","year":"2015","journal-title":"Braz J Med Biol Res"},{"key":"ref8","first-page":"B4778","article-title":"Crohn&apos;s disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort","volume":"61","author":"J Burisch","year":"2014","journal-title":"Dan Med J"},{"key":"ref9","first-page":"1","article-title":"Maintenance therapy options for ulcerative colitis","volume":"30","author":"M Chaparro","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"ref10","first-page":"1235","article-title":"Patient considerations in the management of ulcerative colitis\u2014role of vedolizumab","volume":"19","author":"M Kothari","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11894-015-0466-9","article-title":"Ulcerative colitis: update on medical management","volume":"17","author":"HN Iskandar","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"key":"ref12","first-page":"CD006790","article-title":"Type I interferons for induction of remission in ulcerative colitis","volume":"9","author":"Y Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jcph.649","article-title":"Assessment of disease related therapeutic protein drug-drug interaction for etrolizumab in patients with moderately to severely active ulcerative colitis","volume":"56","author":"X Wei","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/MIB.0000000000000562","article-title":"Adherence to rectal mesalamine in patients with ulcerative colitis","volume":"21","author":"M Boyle","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"ref15","first-page":"1323","article-title":"Ulcerative colitis: diagnosis and treatment","volume":"76","author":"RC Langan","year":"2007","journal-title":"Am Fam Physician"},{"key":"ref16","first-page":"CD008414","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn&apos;s disease","volume":"19","author":"M Gordon","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8776","DOI":"10.3748\/wjg.v21.i29.8776","article-title":"Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2","volume":"21","author":"S Tanida","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00384-015-2318-3","article-title":"Mesalazine-induced eosinophilic pneumonia in a patient with ulcerative colitis disease: a case report and literature review","volume":"31","author":"AI Franco","year":"2016","journal-title":"Int J Colorectal Dis"},{"key":"ref19","first-page":"2013","article-title":"Mesalazine-induced lung fibrosis","volume":"9","author":"E Alskaf","year":"2013","journal-title":"BMJ Case Rep"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.3748\/wjg.v19.i34.5665","article-title":"5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis","volume":"19","author":"R D\u2019Inc\u00e0","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"WJ Sandborn","year":"2003","journal-title":"Alim Pharm Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1023\/A:1015938706685","article-title":"Pharmacokinetics of sulfasalazine metabolites in rats following concominant oral administration of riboflavin","volume":"6","author":"S Chungi","year":"1989","journal-title":"Pharm Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.1988.tb03301.x","article-title":"Absorption of 5-aminosalicylic acid from colon and rectum","volume":"25","author":"R D'Inc\u00e0","year":"1988","journal-title":"Brit J Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"U Klotz","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"ref25","article-title":"Once daily versus multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis","author":"W Li","year":"2016","journal-title":"Colorectal Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4292\/wjgpt.v6.i4.137","article-title":"Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?","volume":"6","author":"B Ye","year":"2015","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CEG.S35691","article-title":"Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis","volume":"7","author":"SK B\u00f6hm","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/ecp.12.2","article-title":"Mesalamine in the treatment and maintenance of remission of ulcerative colitis","volume":"5","author":"M Ham","year":"2012","journal-title":"Exp Rev Clin Pharmacol"},{"key":"ref29","first-page":"111","article-title":"Maintaining remission in ulcerative colitis\u2014role of once daily extended-release mesalamine","volume":"5","author":"L Oliveira","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"ref30","first-page":"136","article-title":"A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy","volume":"16","author":"D Parakkal","year":"2010","journal-title":"World J Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.gtc.2010.08.011","article-title":"Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease","volume":"39","author":"I Sonu","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.bjp.0707358","article-title":"Myeloperoxidase: a target for new drug development?","volume":"152","author":"E Malle","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.2174\/1381612811319120008","article-title":"Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations","volume":"19","author":"LA Ram\u00edrez Dur\u00e1n","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"Suppl","key":"ref34","doi-asserted-by":"crossref","first-page":"621.1","DOI":"10.1096\/fasebj.29.1_supplement.621.1","article-title":"<italic>In vivo<\/italic> evaluation of two 5-aminosalicylic acid derivatives considered as potential therapeutic agents","volume":"29","author":"M Guti\u00e9rrez S\u00e1nchez","year":"2015","journal-title":"FASEB J"},{"key":"ref35","unstructured":"Alem\u00e1n Gonz\u00e1lez-Duhart D. Evaluaci\u00f3n experimental de derivados ar\u00edlicos como posibles inhibidores de mieloperoxidasa y estabilizadores de radicales libres, en un modelo de diabetes mellitus tipo 2. Tesis de Maestr\u00eda en Ciencias en Farmacolog\u00eda. Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional. Ciudad de M\u00e9xico, M\u00e9xico, Agosto 2013."},{"key":"ref36","article-title":"Tesis de Doctorado en Investigaci\u00f3n en Medicina","author":"LA Ram\u00edrez Dur\u00e1n","year":"2013"},{"key":"ref37","unstructured":"OECD Guidelines for the Testing of Chemicals 425: Acute Oral Toxicity\u2014Up-and-Down-Procedure (UDP). 2008."},{"key":"ref38","unstructured":"NOM-062-ZOO-1999. Especificaciones t\u00e9cnicas para la producci\u00f3n, cuidado y uso de los animales de laboratorio, SAGARPA. M\u00e9xico. 1999."},{"key":"ref39","first-page":"5","article-title":"Humane Endpoints in Animal Experiments for Biomedical Research","author":"DB Morton","year":"1999"},{"key":"ref40","article-title":"Guidance for Industry: Bioanalytical Method Validation","year":"2001"},{"key":"ref41","unstructured":"ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text And Methodology Q2(R1). 2005. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ich.org\/products\/guidelines\/quality\/quality-single\/article\/validation-of-analytical-procedures-text-and-methodology.html\" xlink:type=\"simple\">http:\/\/www.ich.org\/products\/guidelines\/quality\/quality-single\/article\/validation-of-analytical-procedures-text-and-methodology.html<\/ext-link>."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.3390\/molecules19055538","article-title":"Pharmacokinetics, tissue distribution, excretion and plasma protein binding studies of wogonin in rats","volume":"19","author":"A Talbi","year":"2014","journal-title":"Molecules"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0379-0738(02)00023-3","article-title":"Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-\u03949-carboxy-tetrahydrocannabinol glucuronide","volume":"126","author":"G Skopp","year":"2002","journal-title":"Forensic Sci Int"},{"key":"ref44","unstructured":"Pascuzzo-Lima C. Farmacolog\u00eda B\u00e1sica. ISBN: 978-980-12-3246\u20139. 2008."},{"key":"ref45","article-title":"Handbook of Pharmaceutical Exicipients","author":"RC Rowe","year":"2009"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-4347(95)00425-4","article-title":"Drug-protein binding sites. New trends in analytical and experimental methodology","volume":"677","author":"J Oravcov\u00e1","year":"1996","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"ref47","article-title":"Farmacolog\u00eda Humana","author":"JA Armijo","year":"2003"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0159889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T12:08:28Z","timestamp":1718712508000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0159889"}},"subtitle":[],"editor":[{"given":"M\u00e1ria A.","family":"Deli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,25]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0159889","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,25]]}}}